organization · Reporting owner
MPM BIOIMPACT LLC
Disclosed activity across 8 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cullinan Therapeutics, Inc.CGEM · Entity 4766 | 10% owner | September 16, 2021 | September 20, 2021 |
| F-star Therapeutics, Inc.SBPH · Entity 115726 | 10% owner | March 25, 2017 | February 06, 2018 |
| Harpoon Therapeutics, Inc.HARP · Entity 11424 | 10% owner | May 28, 2021 | June 02, 2021 |
| Oncorus, Inc.ONCR · Entity 112213 | 10% owner | October 06, 2020 | October 08, 2020 |
| Viracta Therapeutics, Inc.SNSS · Entity 85616 | 10% owner | November 02, 2017 | November 06, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cullinan Therapeutics, Inc.
Report date September 16, 2021 · Filed September 20, 2021
Jointly reported with UBS Oncology Impact Fund L.P., Oncology Impact Fund (Cayman) Management L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,648,268 |
Reported balance
After 2021-09-16 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-09-16 · Sale · Disposed 3,124 · Balance 7,648,268 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.14 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.14 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC.
F4: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.
F-star Therapeutics, Inc.
Report date March 25, 2017 · Filed February 06, 2018
Jointly reported with MPM Oncology Impact Management GP LLC, Oncology Impact Fund (Cayman) Management L.P., UBS Oncology Impact Fund L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 833,839 |
Reported balance
Holding disclosure · report date 2017-03-25 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 833,839 F1: MPM Oncology Impact Management GP LLC ("MPM GP") is the general partner of MPM Oncology Impact Management LP ("MPM Management"), which is the general partner of Oncology Impact Fund (Cayman) Management L.P. ("MPM Cayman"), which is the general partner of UBS Oncology Impact Fund L.P. ("UBS Oncology"). The reported securities are owned indirectly by MPM GP, MPM Management and MPM Cayman, and are owned directly by UBS Oncology. Ansbert Gadicke is the sole member of MPM GP. However, all voting and investment decisions are made by an investment committee comprised of three or more members, including Ansbert Gadicke. Each member of the investment committee expressly disclaims beneficial ownership of the reported securities. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.79 · Expires 2021-11-23 | IndirectSee footnote | Not disclosed |
Reported balance
Holding disclosure · report date 2017-03-25 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: The warrant was issued on November 23, 2016 but did not become exercisable until May 24, 2017. F1: MPM Oncology Impact Management GP LLC ("MPM GP") is the general partner of MPM Oncology Impact Management LP ("MPM Management"), which is the general partner of Oncology Impact Fund (Cayman) Management L.P. ("MPM Cayman"), which is the general partner of UBS Oncology Impact Fund L.P. ("UBS Oncology"). The reported securities are owned indirectly by MPM GP, MPM Management and MPM Cayman, and are owned directly by UBS Oncology. Ansbert Gadicke is the sole member of MPM GP. However, all voting and investment decisions are made by an investment committee comprised of three or more members, including Ansbert Gadicke. Each member of the investment committee expressly disclaims beneficial ownership of the reported securities. |
Filing footnotes · ownership attribution and instrument terms
F1: MPM Oncology Impact Management GP LLC ("MPM GP") is the general partner of MPM Oncology Impact Management LP ("MPM Management"), which is the general partner of Oncology Impact Fund (Cayman) Management L.P. ("MPM Cayman"), which is the general partner of UBS Oncology Impact Fund L.P. ("UBS Oncology"). The reported securities are owned indirectly by MPM GP, MPM Management and MPM Cayman, and are owned directly by UBS Oncology. Ansbert Gadicke is the sole member of MPM GP. However, all voting and investment decisions are made by an investment committee comprised of three or more members, including Ansbert Gadicke. Each member of the investment committee expressly disclaims beneficial ownership of the reported securities.
F2: The warrant was issued on November 23, 2016 but did not become exercisable until May 24, 2017.
Harpoon Therapeutics, Inc.
Report date May 28, 2021 · Filed June 02, 2021
Jointly reported with GADICKE ANSBERT, Oncology Impact Fund (Cayman) Management L.P., MPM Oncology Impact Management GP LLC, UBS Oncology Impact Fund L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 6,374,904 |
Reported balance
After 2021-05-28 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-05-28 · Sale · Disposed 10,685 · Balance 6,374,904 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F2: The shares were sold as follows: 9,392 by UBS Oncology Impact Fund, L.P. ("UBS Oncology") and 1,293 by MPM Asset Management LLC ("AM LLC"). F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.52 to $21.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4: The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. ("BV 2014"), 152,470 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 96,376 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 231,110 by AM LLC and 3,237,851 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. BV LLC is the manager of AM BV2014. Messrs. Evnin, Gadicke and Foley are the members of BV LLC and Messrs. Evnin and Gadicke are the members of AM LLC. Mr. Gadicke is the Managing Member of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 6,371,804 |
Reported balance
After 2021-05-28 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2021-05-28 · Sale · Disposed 3,100 · Balance 6,371,804 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F5: The shares were sold as follows: 2,725 by UBS Oncology and 375 by AM LLC. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.58 to $22.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 230,735 by AM LLC and 3,235,126 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 6,371,704 |
Reported balance
After 2021-05-28 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2021-05-28 · Sale · Disposed 100 · Balance 6,371,704 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F8: The shares were sold as follows: 88 by UBS Oncology and 12 by AM LLC. F9: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 230,723 by AM LLC and 3,235,038 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 6,353,213 |
Reported balance
After 2021-06-01 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2021-06-01 · Sale · Disposed 18,491 · Balance 6,353,213 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F10: The shares were sold as follows: 16,253 by UBS Oncology and 2,238 by AM LLC. F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.74 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F12: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 228,485 by AM LLC and 3,218,785 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 6,328,095 |
Reported balance
After 2021-06-02 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2021-06-02 · Sale · Disposed 25,118 · Balance 6,328,095 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F13: The shares were sold as follows: 22,078 by UBS Oncology and 3,040 by AM LLC. F14: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.24 to $20.76 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F15: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 225,445 by AM LLC and 3,196,707 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021.
F2: The shares were sold as follows: 9,392 by UBS Oncology Impact Fund, L.P. ("UBS Oncology") and 1,293 by MPM Asset Management LLC ("AM LLC").
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.52 to $21.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. ("BV 2014"), 152,470 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 96,376 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 231,110 by AM LLC and 3,237,851 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. BV LLC is the manager of AM BV2014. Messrs. Evnin, Gadicke and Foley are the members of BV LLC and Messrs. Evnin and Gadicke are the members of AM LLC. Mr. Gadicke is the Managing Member of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
F5: The shares were sold as follows: 2,725 by UBS Oncology and 375 by AM LLC.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.58 to $22.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 230,735 by AM LLC and 3,235,126 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
F8: The shares were sold as follows: 88 by UBS Oncology and 12 by AM LLC.
F9: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 230,723 by AM LLC and 3,235,038 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
F10: The shares were sold as follows: 16,253 by UBS Oncology and 2,238 by AM LLC.
F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.74 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F12: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 228,485 by AM LLC and 3,218,785 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
F13: The shares were sold as follows: 22,078 by UBS Oncology and 3,040 by AM LLC.
F14: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.24 to $20.76 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F15: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 225,445 by AM LLC and 3,196,707 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
Oncorus, Inc.
Report date October 06, 2020 · Filed October 08, 2020
Jointly reported with UBS Oncology Impact Fund L.P., Oncology Impact Fund (Cayman) Management L.P., MPM Oncology Impact Management GP LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,377,025 |
Last balance in matching sequence
After 2020-10-06 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2020-10-06 · Conversion · Acquired 1,525,348 · Balance 1,525,348 F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2: The reported securities are held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing member of Oncology GP LLC. F3: The Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Row 2 · 2020-10-06 · Conversion · Acquired 700,453 · Balance 2,225,801 F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2: The reported securities are held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing member of Oncology GP LLC. F3: The Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Row 3 · 2020-10-06 · Purchase · Acquired 151,224 · Balance 2,377,025 F2: The reported securities are held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing member of Oncology GP LLC. F3: The Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. |
| Series A-1 Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-10-06 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-10-06 · Conversion · Disposed 1,525,348 · Balance 0 F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2: The reported securities are held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing member of Oncology GP LLC. F3: The Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. |
| Series B Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-10-06 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-10-06 · Conversion · Disposed 700,453 · Balance 0 F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2: The reported securities are held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing member of Oncology GP LLC. F3: The Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date.
F2: The reported securities are held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing member of Oncology GP LLC.
F3: The Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.
Viracta Therapeutics, Inc.
Report date November 02, 2017 · Filed November 06, 2017
Jointly reported with MPM Oncology Impact Management GP LLC, Oncology Impact Fund (Cayman) Management L.P., UBS Oncology Impact Fund L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 3,331,500 |
Last balance in matching sequence
After 2017-11-06 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2017-11-02 · Purchase · Acquired 25,300 · Balance 3,275,300 F1: MPM Oncology Impact Management GP LLC ("MPM GP") is the general partner of MPM Oncology Impact Management LP ("MPM Management"), which is the general partner of Oncology Impact Fund (Cayman) Management L.P. ("MPM Cayman"), which is the general partner of UBS Oncology Impact Fund L.P. ("UBS Oncology"). The reported securities are owned indirectly by MPM GP, MPM Management and MPM Cayman, and are owned directly by UBS Oncology. Row 2 · 2017-11-03 · Purchase · Acquired 40,000 · Balance 3,315,300 F1: MPM Oncology Impact Management GP LLC ("MPM GP") is the general partner of MPM Oncology Impact Management LP ("MPM Management"), which is the general partner of Oncology Impact Fund (Cayman) Management L.P. ("MPM Cayman"), which is the general partner of UBS Oncology Impact Fund L.P. ("UBS Oncology"). The reported securities are owned indirectly by MPM GP, MPM Management and MPM Cayman, and are owned directly by UBS Oncology. Row 3 · 2017-11-06 · Purchase · Acquired 16,200 · Balance 3,331,500 F1: MPM Oncology Impact Management GP LLC ("MPM GP") is the general partner of MPM Oncology Impact Management LP ("MPM Management"), which is the general partner of Oncology Impact Fund (Cayman) Management L.P. ("MPM Cayman"), which is the general partner of UBS Oncology Impact Fund L.P. ("UBS Oncology"). The reported securities are owned indirectly by MPM GP, MPM Management and MPM Cayman, and are owned directly by UBS Oncology. |
Filing footnotes · ownership attribution and instrument terms
F1: MPM Oncology Impact Management GP LLC ("MPM GP") is the general partner of MPM Oncology Impact Management LP ("MPM Management"), which is the general partner of Oncology Impact Fund (Cayman) Management L.P. ("MPM Cayman"), which is the general partner of UBS Oncology Impact Fund L.P. ("UBS Oncology"). The reported securities are owned indirectly by MPM GP, MPM Management and MPM Cayman, and are owned directly by UBS Oncology.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
TCR2 THERAPEUTICS INC.
Report date June 01, 2023 · Filed June 05, 2023
Jointly reported with UBS Oncology Impact Fund L.P., Oncology Impact Fund (Cayman) Management L.P.
Section 16 reporting ended · disclosed 2023-06-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-06-01 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-06-01 · Other · Disposed 3,370,982 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time"). F2: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). F3: The reported securities were held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). BioImpact Capital LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing partner of BioImpact. F4: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time").
F2: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares").
F3: The reported securities were held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). BioImpact Capital LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing partner of BioImpact.
F4: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein.
Werewolf Therapeutics, Inc.
Report date December 02, 2025 · Filed December 04, 2025
Jointly reported with GADICKE ANSBERT, MPM ONCOLOGY INNOVATIONS FUND LP, UBS Oncology Impact Fund L.P., Oncology Impact Fund (Cayman) Management L.P., MPM Oncology Innovations Fund GP LLC, MPM ASSET MANAGEMENT LLC
Section 16 reporting ended · disclosed 2025-12-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 4,924,566 |
Reported balance
After 2025-12-02 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-12-02 · Sale · Disposed 59,277 · Balance 4,924,566 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2: The shares were sold as follows: 4,070 by MPM Asset Management LLC ("AM LLC"), 25,712 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,715 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 884 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 5,662 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 21,234 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.852 to $0.9246 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F5: The shares are held as follows: 338,231 by AM LLC, 2,135,926 by BV 2014, 142,463 by BV 2014(B), 73,518 by AM BV2014, 468,282 by MPM OIF and 1,766,146 by UBS Oncology. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 4,867,341 |
Reported balance
After 2025-12-03 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2025-12-03 · Sale · Disposed 57,225 · Balance 4,867,341 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6: The shares were sold as follows: 3,929 by AM LLC, 24,821 by BV 2014, 1,656 by BV 2014(B), 854 by AM BV2014, 5,466 by MPM OIF and 20,499 by UBS Oncology. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.9256 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F8: The shares are held as follows: 334,302 by AM LLC, 2,111,105 by BV 2014, 140,807 by BV 2014(B), 72,664 by AM BV2014, 462,816 by MPM OIF and 1,745,647 by UBS Oncology. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 4,784,111 |
Reported balance
After 2025-12-04 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2025-12-04 · Sale · Disposed 83,230 · Balance 4,784,111 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9: The shares were sold as follows: 5,714 by AM LLC, 36,101 by BV 2014, 2,408 by BV 2014(B), 1,243 by AM BV2014, 7,950 by MPM OIF and 29,814 by UBS Oncology. F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.92 to $1.0208 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F11: The shares are held as follows: 328,588 by AM LLC, 2,075,004 by BV 2014, 138,399 by BV 2014(B), 71,421 by AM BV2014, 454,866 by MPM OIF and 1,715,833 by UBS Oncology. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.
F2: The shares were sold as follows: 4,070 by MPM Asset Management LLC ("AM LLC"), 25,712 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,715 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 884 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 5,662 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 21,234 by UBS Oncology Impact Fund L.P. ("UBS Oncology").
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.852 to $0.9246 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
F5: The shares are held as follows: 338,231 by AM LLC, 2,135,926 by BV 2014, 142,463 by BV 2014(B), 73,518 by AM BV2014, 468,282 by MPM OIF and 1,766,146 by UBS Oncology.
F6: The shares were sold as follows: 3,929 by AM LLC, 24,821 by BV 2014, 1,656 by BV 2014(B), 854 by AM BV2014, 5,466 by MPM OIF and 20,499 by UBS Oncology.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.9256 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8: The shares are held as follows: 334,302 by AM LLC, 2,111,105 by BV 2014, 140,807 by BV 2014(B), 72,664 by AM BV2014, 462,816 by MPM OIF and 1,745,647 by UBS Oncology.
F9: The shares were sold as follows: 5,714 by AM LLC, 36,101 by BV 2014, 2,408 by BV 2014(B), 1,243 by AM BV2014, 7,950 by MPM OIF and 29,814 by UBS Oncology.
F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.92 to $1.0208 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11: The shares are held as follows: 328,588 by AM LLC, 2,075,004 by BV 2014, 138,399 by BV 2014(B), 71,421 by AM BV2014, 454,866 by MPM OIF and 1,715,833 by UBS Oncology.
iTeos Therapeutics, Inc.
Report date May 13, 2025 · Filed May 15, 2025
Jointly reported with GADICKE ANSBERT, Oncology Impact Fund (Cayman) Management L.P., UBS Oncology Impact Fund L.P.
Section 16 reporting ended · disclosed 2025-05-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 3,452,797 |
Reported balance
After 2025-05-13 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-05-13 · Sale · Disposed 1,031,931 · Balance 3,452,797 F1: The shares were sold as follows: 355,406 by MPM BioVentures 2014, L.P. ("BV 2014"), 22,386 by MPM BioVentures 2014 (B), L.P. ("BV 2014(B)"), 12,233 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 224,467 by MPM BioVentures 2018, L.P. ("BV 2018"), 11,267 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)"), 4,432 by MPM Asset Management Investors BV2018 LLC ("AM BV2018") and 401,740 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC. F2: MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.73 to $8.34 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4: The shares are held as follows: 1,189,174 by BV 2014, 74,903 by BV 2014(B), 40,931 by AM BV2014, 751,056 by BV 2018, 37,699 by BV 2018(B), 14,831 by AM BV2018 and 1,344,203 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold as follows: 355,406 by MPM BioVentures 2014, L.P. ("BV 2014"), 22,386 by MPM BioVentures 2014 (B), L.P. ("BV 2014(B)"), 12,233 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 224,467 by MPM BioVentures 2018, L.P. ("BV 2018"), 11,267 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)"), 4,432 by MPM Asset Management Investors BV2018 LLC ("AM BV2018") and 401,740 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC.
F2: MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.73 to $8.34 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The shares are held as follows: 1,189,174 by BV 2014, 74,903 by BV 2014(B), 40,931 by AM BV2014, 751,056 by BV 2018, 37,699 by BV 2018(B), 14,831 by AM BV2018 and 1,344,203 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 10, 2021 Filed Sep 13, 2021 23:02 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 11,313 | $27.86 | $315,180.18 |
DisclosureSEC source: 0001209191-21-055745 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,852,455 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F6 · shares: The shares were sold as follows: 4,027 by BV 2014, 139 by AM BV2014, 2,544 by BV 2018, 50 by AM BV2018 and 4,553 by UBS Oncology. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.455 to $28.45 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F8 · ownership.nature: The shares are held as follows: 2,025,944 by BV 2014, 107,713 by BV 2014(B), 69,732 by AM BV2014, 1,279,542 by BV 2018, 54,213 by BV 2018(B), 25,252 by AM BV2018 and 2,290,059 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document |
| September 10, 2021 Filed Sep 13, 2021 22:24 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 5,931 | $29.04 | $172,236.24 |
DisclosureSEC source: 0001209191-21-055726 · doc4.xml · nonDerivative · entry 2 UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,668,518 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.105 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.direct: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Read SEC document |
| September 09, 2021 Filed Sep 13, 2021 23:02 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 38,028 | $28.97 | $1,101,671.16 |
DisclosureSEC source: 0001209191-21-055745 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,863,768 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F2 · shares: The shares were sold as follows: 13,539 by MPM BioVentures 2014, L.P. ("BV 2014"), 466 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 8,551 by MPM BioVentures 2018, L.P. ("BV 2018"), 169 by MPM Asset Management Investors BV2018 LLC ("AM BV2018") and 15,303 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC. F3 · shares: BioImpact Capital LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.29 to $29.27 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The shares are held as follows: 2,029,971 by BV 2014, 107,713 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 69,871 by AM BV2014, 1,282,086 by BV 2018, 54,213 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)"), 25,302 by AM BV2018 and 2,294,612 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document |
| September 09, 2021 Filed Sep 13, 2021 22:24 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 13,727 | $29.35 | $402,887.45 |
DisclosureSEC source: 0001209191-21-055726 · doc4.xml · nonDerivative · entry 1 UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,674,449 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.56 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.direct: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Read SEC document |
| September 08, 2021 Filed Sep 8, 2021 23:19 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 1,573 | $29.10 | $45,774.30 |
DisclosureSEC source: 0001209191-21-055212 · doc4.xml · nonDerivative · entry 4 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,901,796 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F12 · shares: The shares were sold as follows: 560 by BV 2014, 19 by AM BV2014, 354 by BV 2018, 7 by AM BV2018 and 633 by UBS Oncology. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.04 to $29.21 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F14 · ownership.nature: The shares are held as follows: 2,043,510 by BV 2014, 107,713 by BV 2014(B), 70,337 by AM BV2014, 1,290,637 by BV 2018, 54,213 by BV 2018(B), 25,471 by AM BV2018 and 2,309,915 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document |
| September 08, 2021 Filed Sep 8, 2021 23:19 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 18,663 | $28.61 | $533,948.43 |
DisclosureSEC source: 0001209191-21-055212 · doc4.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,903,369 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F9 · shares: The shares were sold as follows: 6,644 by BV 2014, 229 by AM BV2014, 4,196 by BV 2018, 83 by AM BV2018 and 7,511 by UBS Oncology. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.02 to $29.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F11 · ownership.nature: The shares are held as follows: 2,044,070 by BV 2014, 107,713 by BV 2014(B), 70,356 by AM BV2014, 1,290,991 by BV 2018, 54,213 by BV 2018(B), 25,478 by AM BV2018 and 2,310,548 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document |
| September 08, 2021 Filed Sep 8, 2021 22:20 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 10,842 | $29.11 | $315,610.62 |
DisclosureSEC source: 0001209191-21-055203 · doc4.xml · nonDerivative · entry 3 UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,688,176 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.185 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.direct: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Read SEC document |
| September 07, 2021 Filed Sep 8, 2021 23:19 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | OtherCommon Stock | 31,340 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-055212 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,922,032 F6 · kind: Represents a pro rata in-kind distribution from BV 2014(B) and BV 2018(B) to its respectve limited partners for no consideration. F7 · shares: The shares were distributed as follows: 20,848 shares by BV 2014(B) and 10,492 shares by BV 2018(B). F8 · ownership.nature: The shares are held as follows: 2,050,714 by BV 2014, 107,713 by BV 2014(B), 70,585 by AM BV2014, 1,295,187 by BV 2018, 54,213 by BV 2018(B), 25,561 by AM BV2018 and 2,318,059 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document |
| September 07, 2021 Filed Sep 8, 2021 23:19 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 50,996 | $29.18 | $1,488,063.28 |
DisclosureSEC source: 0001209191-21-055212 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,953,372 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F2 · shares: The shares were sold as follows: 18,156 by MPM BioVentures 2014, L.P. ("BV 2014"), 625 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 11,467 by MPM BioVentures 2018, L.P. ("BV 2018"), 226 by MPM Asset Management Investors BV2018 LLC ("AM BV2018") and 20,522 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC. F3 · shares: BioImpact Capital LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.89 to $29.64 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The shares are held as follows: 2,050,714 by BV 2014, 128,561 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 70,585 by AM BV2014, 1,295,187 by BV 2018, 64,705 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)"), 25,561 by AM BV2018 and 2,318,059 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document |
| September 07, 2021 Filed Sep 8, 2021 22:20 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 25,067 | $29.04 | $727,945.68 |
DisclosureSEC source: 0001209191-21-055203 · doc4.xml · nonDerivative · entry 2 UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,699,018 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.22 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.direct: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Read SEC document |
| September 03, 2021 Filed Sep 8, 2021 22:20 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 12,731 | $29.60 | $376,837.60 |
DisclosureSEC source: 0001209191-21-055203 · doc4.xml · nonDerivative · entry 1 UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,724,085 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.95 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.direct: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Read SEC document |
| September 02, 2021 Filed Sep 2, 2021 21:26 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 15,757 | $29.46 | $464,201.22 |
DisclosureSEC source: 0001209191-21-054518 · doc4.xml · nonDerivative · entry 4 UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,736,816 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.direct: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 21:26 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 5,714 | $29.47 | $168,391.58 |
DisclosureSEC source: 0001209191-21-054518 · doc4.xml · nonDerivative · entry 3 UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,752,573 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.77 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.direct: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 21:26 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 1,553 | $30.14 | $46,807.42 |
DisclosureSEC source: 0001209191-21-054518 · doc4.xml · nonDerivative · entry 2 UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,758,287 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.01 to $30.19 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.direct: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 21:26 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 1,285 | $29.43 | $37,817.55 |
DisclosureSEC source: 0001209191-21-054518 · doc4.xml · nonDerivative · entry 1 UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,759,840 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.83 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.direct: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Read SEC document |
| August 30, 2021 Filed Aug 31, 2021 20:47 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 31,001 | $29.30 | $908,329.30 |
DisclosureSEC source: 0001209191-21-054093 · doc4.xml · nonDerivative · entry 2 UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,761,125 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.84 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.direct: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Read SEC document |
| August 27, 2021 Filed Aug 31, 2021 20:47 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 13,357 | $29.09 | $388,555.13 |
DisclosureSEC source: 0001209191-21-054093 · doc4.xml · nonDerivative · entry 1 UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,792,126 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.38 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.direct: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Read SEC document |
| August 25, 2021 Filed Aug 25, 2021 23:42 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 1,713 | $29.09 | $49,831.17 |
DisclosureSEC source: 0001209191-21-053380 · doc4.xml · nonDerivative · entry 3 UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,805,483 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.01 to $29.47 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC. F4 · ownership.direct: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Read SEC document |
| August 24, 2021 Filed Aug 25, 2021 23:42 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 50,822 | $29.48 | $1,498,232.56 |
DisclosureSEC source: 0001209191-21-053380 · doc4.xml · nonDerivative · entry 2 UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,807,196 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.15 to $29.715 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC. F4 · ownership.direct: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 23:42 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 53,359 | $29.11 | $1,553,280.49 |
DisclosureSEC source: 0001209191-21-053380 · doc4.xml · nonDerivative · entry 1 UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,858,018 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.41 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC. F4 · ownership.direct: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Read SEC document |
| August 11, 2021 Filed Aug 12, 2021 20:55 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 2,510 | $29.05 | $72,915.50 |
DisclosureSEC source: 0001209191-21-051148 · doc4.xml · nonDerivative · entry 1 UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,911,377 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.13 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC. F4 · ownership.direct: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Read SEC document |
| June 02, 2021 Filed Jun 2, 2021 22:09 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 25,118 | $20.50 | $514,919.00 |
DisclosureSEC source: 0001209191-21-037379 · doc4.xml · nonDerivative · entry 5 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,328,095 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F13 · shares: The shares were sold as follows: 22,078 by UBS Oncology and 3,040 by AM LLC. F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.24 to $20.76 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F15 · ownership.nature: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 225,445 by AM LLC and 3,196,707 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 22:09 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 18,491 | $20.44 | $377,956.04 |
DisclosureSEC source: 0001209191-21-037379 · doc4.xml · nonDerivative · entry 4 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,353,213 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F10 · shares: The shares were sold as follows: 16,253 by UBS Oncology and 2,238 by AM LLC. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.74 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F12 · ownership.nature: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 228,485 by AM LLC and 3,218,785 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 22:09 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 100 | $22.60 | $2,260.00 |
DisclosureSEC source: 0001209191-21-037379 · doc4.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,371,704 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F8 · shares: The shares were sold as follows: 88 by UBS Oncology and 12 by AM LLC. F9 · ownership.nature: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 230,723 by AM LLC and 3,235,038 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 22:09 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 3,100 | $21.92 | $67,952.00 |
DisclosureSEC source: 0001209191-21-037379 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,371,804 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F5 · shares: The shares were sold as follows: 2,725 by UBS Oncology and 375 by AM LLC. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.58 to $22.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7 · ownership.nature: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 230,735 by AM LLC and 3,235,126 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 22:09 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 10,685 | $20.88 | $223,102.80 |
DisclosureSEC source: 0001209191-21-037379 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,374,904 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F2 · shares: The shares were sold as follows: 9,392 by UBS Oncology Impact Fund, L.P. ("UBS Oncology") and 1,293 by MPM Asset Management LLC ("AM LLC"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.52 to $21.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. ("BV 2014"), 152,470 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 96,376 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 231,110 by AM LLC and 3,237,851 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. BV LLC is the manager of AM BV2014. Messrs. Evnin, Gadicke and Foley are the members of BV LLC and Messrs. Evnin and Gadicke are the members of AM LLC. Mr. Gadicke is the Managing Member of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 27, 2021 Filed May 27, 2021 23:40 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 13,961 | $20.26 | $282,849.86 |
DisclosureSEC source: 0001209191-21-036349 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,385,589 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F5 · shares: The shares were sold as follows: 12,271 by UBS Oncology and 1,690 by AM LLC. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.05 to $20.49 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7 · ownership.nature: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 232,403 by AM LLC and 3,247,243 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 26, 2021 Filed May 27, 2021 23:40 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 3,198 | $20.04 | $64,087.92 |
DisclosureSEC source: 0001209191-21-036349 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,399,550 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F2 · shares: The shares were sold as follows: 2,811 by UBS Oncology Impact Fund, L.P. ("UBS Oncology") and 387 by MPM Asset Management LLC ("AM LLC"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.95 to $20.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. ("BV 2014"), 152,470 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 96,376 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 234,093 by AM LLC and 3,259,514 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. BV LLC is the manager of AM BV2014. Messrs. Evnin, Gadicke and Foley are the members of BV LLC and Messrs. Evnin and Gadicke are the members of AM LLC. Mr. Gadicke is the Managing Member of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 24, 2021 Filed May 25, 2021 00:11 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 5,000 | $20.12 | $100,600.00 |
DisclosureSEC source: 0001209191-21-035558 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,402,748 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F5 · shares: The shares were sold as follows: 4,395 by UBS Oncology and 605 by AM LLC. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.95 to $20.355 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7 · ownership.nature: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 234,480 by AM LLC and 3,262,325 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 21, 2021 Filed May 25, 2021 00:11 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 10,907 | $20.21 | $220,430.47 |
DisclosureSEC source: 0001209191-21-035558 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,407,748 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F2 · shares: The shares were sold as follows: 9,587 by UBS Oncology Impact Fund, L.P. ("UBS Oncology") and 1,320 by MPM Asset Management LLC ("AM LLC"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.95 to $20.42 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. ("BV 2014"), 152,470 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 96,376 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 235,085 by AM LLC and 3,266,720 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. BV LLC is the manager of AM BV2014. Messrs. Evnin, Gadicke and Foley are the members of BV LLC and Messrs. Evnin and Gadicke are the members of AM LLC. Mr. Gadicke is the Managing Member of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 20, 2021 Filed May 20, 2021 23:20 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 11,713 | $20.34 | $238,242.42 |
DisclosureSEC source: 0001209191-21-034626 · doc4.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,418,655 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F8 · shares: The shares were sold as follows: 10,295 by UBS Oncology and 1,418 by AM LLC. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.07 to $20.84 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F10 · ownership.nature: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 236,405 by AM LLC and 3,276,307 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 19, 2021 Filed May 20, 2021 23:20 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 17,833 | $20.39 | $363,614.87 |
DisclosureSEC source: 0001209191-21-034626 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,430,368 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F5 · shares: The shares were sold as follows: 15,675 by UBS Oncology and 2,158 by AM LLC. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.95 to $20.71 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7 · ownership.nature: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 237,823 by AM LLC and 3,286,602 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 18, 2021 Filed May 20, 2021 23:20 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 18,402 | $20.67 | $380,369.34 |
DisclosureSEC source: 0001209191-21-034626 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,448,201 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F2 · shares: The shares were sold as follows: 16,175 by UBS Oncology Impact Fund, L.P. ("UBS Oncology") and 2,227 by MPM Asset Management LLC ("AM LLC"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.26 to $20.95 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. ("BV 2014"), 152,470 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 96,376 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 239,981 by AM LLC and 3,302,277 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. BV LLC is the manager of AM BV2014. Messrs. Evnin, Gadicke and Foley are the members of BV LLC and Messrs. Evnin and Gadicke are the members of AM LLC. Mr. Gadicke is the Managing Member of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 17, 2021 Filed May 17, 2021 21:23 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 4,666 | $20.07 | $93,646.62 |
DisclosureSEC source: 0001209191-21-033213 · doc4.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,466,603 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F8 · shares: The shares were sold as follows: 4,101 by UBS Oncology and 565 by AM LLC. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.95 to $20.435 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F10 · ownership.nature: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 242,208 by AM LLC and 3,318,452 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 14, 2021 Filed May 17, 2021 21:23 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 6,900 | $20.04 | $138,276.00 |
DisclosureSEC source: 0001209191-21-033213 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,471,269 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F5 · shares: The shares were sold as follows: 6,065 by UBS Oncology and 835 by AM LLC. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.96 to $20.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7 · ownership.nature: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 242,773 by AM LLC and 3,322,553 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 13, 2021 Filed May 17, 2021 21:23 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 4,855 | $20.06 | $97,391.30 |
DisclosureSEC source: 0001209191-21-033213 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,478,169 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F2 · shares: The shares were sold as follows: 4,267 by UBS Oncology Impact Fund, L.P. ("UBS Oncology") and 588 by MPM Asset Management LLC ("AM LLC"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.95 to $20.56 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. ("BV 2014"), 152,470 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 96,376 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 243,608 by AM LLC and 3,328,618 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. BV LLC is the manager of AM BV2014. Messrs. Evnin, Gadicke and Foley are the members of BV LLC and Messrs. Evnin and Gadicke are the members of AM LLC. Mr. Gadicke is the Managing Member of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 12, 2021 Filed May 12, 2021 22:09 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 29,684 | $20.53 | $609,412.52 |
DisclosureSEC source: 0001209191-21-032178 · doc4.xml · nonDerivative · entry 5 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,483,024 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F14 · shares: The shares were sold as follows: 26,092 by UBS Oncology and 3,592 by AM LLC. F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.845 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F16 · ownership.nature: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 244,196 by AM LLC and 3,332,885 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 11, 2021 Filed May 12, 2021 22:09 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 7,672 | $21.51 | $165,024.72 |
DisclosureSEC source: 0001209191-21-032178 · doc4.xml · nonDerivative · entry 4 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,512,708 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F11 · shares: The shares were sold as follows: 6,744 by UBS Oncology and 928 by AM LLC. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.38 to $21.73 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F13 · ownership.nature: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 247,788 by AM LLC and 3,358,977 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 11, 2021 Filed May 12, 2021 22:09 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 13,773 | $20.96 | $288,682.08 |
DisclosureSEC source: 0001209191-21-032178 · doc4.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,520,380 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F8 · shares: The shares were sold as follows: 12,106 by UBS Oncology and 1,667 by AM LLC. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.38 to $21.375 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F10 · ownership.nature: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 248,716 by AM LLC and 3,365,721 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 10, 2021 Filed May 12, 2021 22:09 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 411 | $22.46 | $9,231.06 |
DisclosureSEC source: 0001209191-21-032178 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,534,153 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F5 · shares: The shares were sold as follows: 361 by UBS Oncology and 50 by AM LLC. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.22 to $22.72 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7 · ownership.nature: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 250,383 by AM LLC and 3,377,827 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 10, 2021 Filed May 12, 2021 22:09 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 16,722 | $21.78 | $364,205.16 |
DisclosureSEC source: 0001209191-21-032178 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,534,564 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F2 · shares: The shares were sold as follows: 14,698 by UBS Oncology Impact Fund, L.P. ("UBS Oncology") and 2,024 by MPM Asset Management LLC ("AM LLC"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.16 to $22.04 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. ("BV 2014"), 152,470 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 96,376 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 250,433 by AM LLC and 3,378,188 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. BV LLC is the manager of AM BV2014. Messrs. Evnin, Gadicke and Foley are the members of BV LLC and Messrs. Evnin and Gadicke are the members of AM LLC. Mr. Gadicke is the Managing Member of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 05, 2021 Filed May 6, 2021 20:05 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 59 | $23.09 | $1,362.31 |
DisclosureSEC source: 0001209191-21-030611 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,551,286 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F5 · shares: The shares were sold as follows: 52 by UBS Oncology and 7 by AM LLC. F6 · ownership.nature: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 252,457 by AM LLC and 3,392,886 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 05, 2021 Filed May 6, 2021 20:05 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 10,113 | $22.52 | $227,744.76 |
DisclosureSEC source: 0001209191-21-030611 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,551,345 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F2 · shares: The shares were sold as follows: 8,889 by UBS Oncology Impact Fund, L.P. ("UBS Oncology") and 1,224 by MPM Asset Management LLC ("AM LLC"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.075 to $23.02 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. ("BV 2014"), 152,470 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 96,376 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 252,464 by AM LLC and 3,392,938 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. BV LLC is the manager of AM BV2014. Messrs. Evnin, Gadicke and Foley are the members of BV LLC and Messrs. Evnin and Gadicke are the members of AM LLC. Mr. Gadicke is the Managing Member of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 04, 2021 Filed May 4, 2021 21:43 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 3,500 | $23.33 | $81,655.00 |
DisclosureSEC source: 0001209191-21-029994 · doc4.xml · nonDerivative · entry 5 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,561,458 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F14 · shares: The shares were sold as follows: 3,076 by UBS Oncology and 424 by AM LLC. F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.29 to $23.40 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F16 · ownership.nature: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 253,688 by AM LLC and 3,401,827 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 04, 2021 Filed May 4, 2021 21:43 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 26,230 | $23.03 | $604,076.90 |
DisclosureSEC source: 0001209191-21-029994 · doc4.xml · nonDerivative · entry 4 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,564,958 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F11 · shares: The shares were sold as follows: 23,056 by UBS Oncology and 3,174 by AM LLC. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.29 to $23.27 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F13 · ownership.nature: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 254,112 by AM LLC and 3,404,903 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:19 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | ConversionSeries B Preferred Stock · Derivative | 12,899,925 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-030625 · doc4.xml · derivative · entry 5 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,488,033 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock and Series B Preferred Stock converted into common stock on a 8.6691-for-1 basis into the number of shares of common stock shown in Column 7 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock and Series B Preferred Stock converted into common stock on a 8.6691-for-1 basis into the number of shares of common stock shown in Column 7 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock and Series B Preferred Stock converted into common stock on a 8.6691-for-1 basis into the number of shares of common stock shown in Column 7 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F9 · derivative.underlying_shares: The shares were held as follows: 693,667 by BV 2014, 46,266 by BV 2014(B), 23,876 by AM BV2014, 152,083 by MPM OIF and 572,141 by UBS Oncology. F8 · ownership.nature: No securities held by the Reporting Persons. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:19 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | ConversionSeries A Preferred Stock · Derivative | 38,817,998 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-030625 · doc4.xml · derivative · entry 4 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 4,477,742 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock and Series B Preferred Stock converted into common stock on a 8.6691-for-1 basis into the number of shares of common stock shown in Column 7 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock and Series B Preferred Stock converted into common stock on a 8.6691-for-1 basis into the number of shares of common stock shown in Column 7 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock and Series B Preferred Stock converted into common stock on a 8.6691-for-1 basis into the number of shares of common stock shown in Column 7 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F7 · derivative.underlying_shares: The shares were held as follows: 2,087,358 by BV 2014, 139,224 by BV 2014(B), 71,848 by AM BV2014, 457,643 by MPM OIF and 1,721,669 by UBS Oncology. F8 · ownership.nature: No securities held by the Reporting Persons. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:19 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | PurchaseCommon Stock | 245,000 | $16.00 | $3,920,000.00 |
DisclosureSEC source: 0001209191-21-030625 · doc4.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,672,183 F5 · shares: The shares were purchased as follows: 114,210 by BV 2014, 7,618 by BV 2014(B), 3,931 by AM BV2014, 25,040 by MPM OIF and 94,201 by UBS Oncology. F6 · ownership.nature: The shares are held as follows: 461,408 by AM LLC, 2,895,235 by BV 2014, 193,108 by BV 2014(B), 99,655 by AM BV2014, 634,766 by MPM OIF and 2,388,011 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:19 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | ConversionCommon Stock | 1,488,033 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-030625 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,427,183 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock and Series B Preferred Stock converted into common stock on a 8.6691-for-1 basis into the number of shares of common stock shown in Column 7 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F4 · ownership.nature: The shares are held as follows: 461,408 by AM LLC, 2,781,025 by BV 2014, 185,490 by BV 2014(B), 95,724 by AM BV2014, 609,726 by MPM OIF and 2,293,810 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:19 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | ConversionCommon Stock | 4,477,742 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-030625 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,939,150 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock and Series B Preferred Stock converted into common stock on a 8.6691-for-1 basis into the number of shares of common stock shown in Column 7 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.nature: The shares are held as follows: 461,408 by MPM Asset Management LLC ("AM LLC"), 2,087,358 by MPM BioVentures 2014, L.P. ("BV 2014"), 139,224 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 71,848 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 457,643 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 1,721,669 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Ansbert Gadicke is a member of AM LLC and a Managing Director of BV LLC. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. F3 · ownership.nature: MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is the managing director of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.